The Fragile Histidine Triad gene and breast cancer

Medical Science Monitor

Volumn 8, Issue 7, 2002, Pages

  Yang, Qifeng ^a   Yoshimura, Goro ^a   Sakurai, Takeo ^a   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; FHIT; Gene therapy; Hypermethylation; Loss of heterozygosity

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; ACID ANHYDRIDE HYDROLASE; TUMOR PROTEIN;

BREAST CANCER; CANCER THERAPY; CHROMOSOME 3P; DNA METHYLATION; FEMALE; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CHROMOSOME 3; GENE DELETION; GENETICS; METABOLISM;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMAN; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; SUPPORT, NON-U.S. GOV'T; ACID ANHYDRIDE HYDROLASES; HUMANS;

EID: 0036327283     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multitracial and multiethnic populations
2. Antioncogenes and human cancer
3. Heterogeneity for allelic loss in human breast cancer
4. Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cM interval of 8p22-p23. I
5. Biallelic inactivation of retinoic acid receptor (2 gene by epigenetic change in breast cancer
6. Localization of breast cancer tumor-suppressor gene to a 3-cM interval within chromosomal region 16q22
7. Allelic loss in human intrahepatic cholangiocarcinoma: Correlation between chromosome 8p22 and tumor progression
8. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3; 8) breakpoint, is abnormal in digestive tract cancers
9. Fhit, a putative tumor suppressor in humans, is a dinucleoside 3′, 5‴-P1, P3-triphosphate hydrolase
10. Replacement of Fhit in cancer cells suppresses tumorigenicity
11. Muir-Torre-like syndrome in Fhit deficient mice
12. The tumor spectrum in Fhit deficient mice
13. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands
14. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancer
15. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas
16. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer
17. The FHIT gene at 3p14.2 is abnormal in breast carcinomas
18. Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and (-cat genes in squamous cell carcinoma of the head and neck
19. Mutation prolife of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas
20. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinous pattern of allele loss
21. Alterations of the FHIT gene in breast cancer: Association with tumor progression and patient survival
22. Abnormal FHIT transcripts in human breast carcinomas: A clinicopathological and epidemiological analysis of 62 Japanese cases
23. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma
24. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease
25. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma
26. Cancer cells exhibit a mutator pbenotype
27. Lessons from hereditary colorectal cancer
28. Mismatch repair defects in human carcinogenesis
29. Female embryonic lethality in mice nullizygous for both Msh2 and p53
30. Differential cellular expression of the human MSH2 repair enzyme in small and large intestine
31. Mismatch repair, genetic stability, and cancer
32. Genomic FHIT analysis m RER+ and RER- adenocarcinomas of the pancreas
33. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma
34. Loss of Msh2 is not associated with FHIT deletion in breast carcinomas
35. A central role for chromosome breakage in gene amplication, deletion formation, and amplicon integration
36. Loss of heterozygosity induced by a chromosomal double-strand break
37. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP 17, CYPIA1, and COMT: A multigenic study on cancer susceptibility
38. Molecular origin of cancer: Catechol estrogen-3, 4-quinones as endogenous tumor initiators
39. In vitro repair of synthetic ionizing radiation-induced multiply damaged DNA sites
40. Mutation and childhood cancer: A probabilistic model for the incidence of retinoblastoma
41. Tumor suppressor genes and human cancer
42. Alterations in DNA methylation: A fundamental aspect of neoplasia
43. Cancer epigenetics comes of age
44. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated Fragile histidine triad (FHIT) gene overexpression
45. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines
46. FHIT gene therapy prevents tumor development in Fhit-deficient mice